A significantly higher proportion of residents with stage 3–5 CKD used insulin (46.4% versus 40.1%, P = 0.006), and a lower proportion used OAD or GLP-1 (28.4% versus 34.6%, P = 0.004) as compared to those without stage 3–5 CKD (Table 4). The gene discussed is INS; the disease is chronic kidney disease.